Compare the best Samsung Watch CGM apps and Wear OS tools for blood sugar readings, including Dexcom G6, Gluroo, and xDrip+.

Dexcom says stolen G7 sensors from two scrapped lots were sold through unauthorized channels, creating infection and reading-failure risks. Medical device maker Dexcom says two lots of its Dexcom G7 ...

May 26 (Reuters) - Medical device maker Dexcom (DXCM.O), opens new tab said on Tuesday some of its glucose sensors slated for destruction were instead stolen and ‌sold, prompting the company to warn ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Mario covers technology in health care, including FDA regulation of artificial intelligence; how Medicare pays for health tech; the use of AI in clinical care; mental health chatbots; and consumer ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

In December, online rumors hinted at the fact that Dexcom may be planning to sunset its G6 CGM sensor model. The company has now started to notify patients of the discontinuation plan. The company ...

Why have investors been so bearish on DexCom? DexCom makes continuous glucose monitoring (CGM) devices, which are crucial for people with diabetes who have high glucose levels. There are also CGMs now ...

Dexcom has issued a Class I recall for its G6 glucose sensor Android application due to a defect that causes the app to crash unexpectedly. As a result of the app terminating, users could miss ...

See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. People with Type 1 diabetes are estimated to make up to 180 more ...

DexCom receives a BUY rating due to strong growth, expanding margins, and the launch of Stelo, the first OTC CGM for non-insulin users. DXCM raised its 2025 outlook, targeting $4.6B+ in revenue, 62% ...